Beta-lactamases identified in clinical isolates of Pseudomonas aeruginosa.
The increased prevalence of beta-lactamases in Pseudomonas aeruginosa has begun to reduce the clinical efficacy of beta-lactams against the most common opportunistic pathogen. Of over 800 beta-lactamases identified from Gram-negative bacilli, at least 120 beta-lactamases have been detected in P. aeruginosa. IMPs and VIMs are predominantly found in P. aeruginosa and like Acinetobacter spp., P. aeruginosa is also a predominant source of OXAs, indicating that P. aeruginosa is a crucial reservoir of beta-lactam resistance determinants. This review summarizes the beta-lactamases identified in clinical isolates of P. aeruginosa, with a particular focus on AmpC-type beta-lactamases, extended-spectrum beta-lactamases, and carbapenemases.
Zhao
Wei-Hua
WH
Department of Microbiology and Immunology, Showa University School of Medicine, Tokyo, Japan. whzhao@med.showa-u.ac.jp
Hu
Zhi-Qing
ZQ
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D011552:Pseudomonas Infections / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism*; D047090:beta-Lactams / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D047090:beta-Lactams; D001618:beta-Lactamases